Corcept Therapeutics received early FDA approval for Lifyorli (relacorilant) to treat platinum-resistant ovarian cancer. Clinical data showed a 35% reduction in risk of death and good tolerability, positioning the drug as a promising new option in ovarian cancer treatment. Analysts expect Lifyorli's growth to offset declines in Corcept's existing drug Korlym, with projected sales between $900 million and $1 billion by 2026. The approval has led to an upgrade of Corcept's stock to Strong Buy due to strong clinical results and a favorable risk/reward profile.
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
The global clinical trials market is projected to grow from $135.51 billion in 2026 to $176.32 billion by 2030, at a CAGR of 6.8%. Growth is fueled by advances in AI-enabled trial design, decentralized and hybrid trial platforms, and increasing deman...
The global hybrid robots market is projected to grow from $5.68 billion in 2026 to $10.03 billion by 2030, with a CAGR of 15.3%. Growth is fueled by advances in AI, autonomous operations, and smart manufacturing, alongside rising demand for robots in...
The global warehouse shuttle software market is projected to grow from $1.57 billion in 2026 to $2.66 billion by 2030, with a CAGR of 14.1%. Growth is fueled by rising e-commerce, warehouse automation, AI-driven orchestration, and robotic material ha...
